Verastem, Inc.

Verastem is a biopharmaceutical company developing cancer treatments in the US. Its products include Avutometinib, an orally available RAF/MEK clamp, and Defactinib, an oral FAK inhibitor. The company has several clinical trials ongoing, including RAMP 301, RAMP 201, FRAME, RAMP 204, and RAMP 205. It has license agreements with Chugai Pharmaceutical Co. and Pfizer Inc. Verastem also has a collaboration agreement with Amgen to evaluate Avutometinibs combination with Amgens KRAS-G12C inhibitor LUMAKRAS. Additionally, the company has a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

6.2 USD

Potential

-100%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.4